K-232 Drug Market

"K-232 Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about K-232 (Ripasudil/Brimonidine) for Glaucoma in Japan. A detailed picture of the K-232 (Ripasudil/Brimonidine) for Glaucoma in Japan for the study period 2019–2032 is provided in this report along with a detailed description of the K-232 (Ripasudil/Brimonidine) for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the K-232 (Ripasudil/Brimonidine) market forecast, analysis for Glaucoma in Japan, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.

K-232 Drug Summary

Ripasudil Hydrochloride Hydrate is a fixed combination eye drop ""Ripasudil Hydrochloride Hydrate"" a Rho kinase inhibitor, and Brimonidine Tartrate, which is being developed for the treatment of primary open-angle glaucoma (POAG) and ocular hypertension.

K-232 is the world’s first fixed combination eye drop containing a combination of Ripasudil hydrochloride hydrate, the active ingredient in the rho-kinase inhibitor Glanatec Ophthalmic Solution 0.4%, and the α2-adrenergic agonist Brimonidine tartrate. Since the drug has a different pharmacological point of action from existing combination eye drops, it can be used in combination with various other treatments for glaucoma and ocular hypertension.

In November 2022, the company received notification from the Ministry of Health, Labor, and Welfare to the effect that the glaucoma and ocular hypertension treatment2 ""GLA-ALPHA Combination Ophthalmic Solution"" (generic name: ripasudil hydrochloride hydrate/brimonidine tartrate3; development code: K-232; hereafter referred to as ""this drug""), a new fixed combination eye drop, had been listed in the National Health Insurance (NHI) drug price standard.

K-232 (GLA-ALPHA combination ophthalmic solution) was granted manufacturing and marketing approval in Japan for the treatment of glaucoma and ocular hypertension in September 2022.

 

Scope of the K-232 Drug Market Report

The report provides insights into:

• A comprehensive product overview including the K-232 (Ripasudil/Brimonidine) description, mechanism of action, dosage and administration, research and development activities in Glaucoma.

• Elaborated details on K-232 (Ripasudil/Brimonidine) regulatory milestones and other development activities have been provided in this report.

• The report also highlights the K-232 (Ripasudil/Brimonidine) research and development activity in Glaucoma in detail across Japan.

• The report also covers the patents information with expiry timeline around K-232 (Ripasudil/Brimonidine).

• The report contains forecasted sales of K-232 (Ripasudil/Brimonidine) for Glaucoma till 2032.

• Comprehensive coverage of the late-stage emerging therapies for Glaucoma.

• The report also features the SWOT analysis with analyst views for K-232 (Ripasudil/Brimonidine) in Glaucoma.

 

K-232 Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

K-232 (Ripasudil/Brimonidine) Analytical Perspective by DelveInsight

• In-depth K-232 (Ripasudil/Brimonidine)  Market Assessment

This report provides a detailed market assessment of K-232 (Ripasudil/Brimonidine) in Glaucoma in Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• K-232 (Ripasudil/Brimonidine)  Clinical Assessment

The report provides the clinical trials information of K-232 (Ripasudil/Brimonidine) in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.

 

K-232 Drug Market Report Highlights  

• In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   

• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence K-232 (Ripasudil/Brimonidine) dominance.

• Other emerging products for Glaucoma are expected to give tough market competition to K-232 (Ripasudil/Brimonidine) and launch of late-stage emerging therapies in the near future will significantly impact the market. 

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of K-232 (Ripasudil/Brimonidine) in Glaucoma.

• Our in-depth analysis of the forecasted sales data of K-232 (Ripasudil/Brimonidine) from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the K-232 (Ripasudil/Brimonidine) in Glaucoma. 

 

Key Questions

• What is the product type, route of administration and mechanism of action of K-232 (Ripasudil/Brimonidine)?

• What is the clinical trial status of the study related to K-232 (Ripasudil/Brimonidine) in Glaucoma and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the K-232 (Ripasudil/Brimonidine) development?

• What are the key designations that have been granted to K-232 (Ripasudil/Brimonidine) for Glaucoma?

• What is the forecasted market scenario of K-232 (Ripasudil/Brimonidine) for Glaucoma?

• What are the forecasted sales of K-232 (Ripasudil/Brimonidine) in Japan?  

• What are the other emerging products available in Glaucoma and how are they giving competition to K-232 (Ripasudil/Brimonidine) for Glaucoma?

• Which are the late-stage emerging therapies under development for the treatment of Glaucoma?